In contrast, a decrease in the expression of p-Y523-PSPC1 is a warning of the synergistic oncogenic activation of PSPC1, nuclear β-catenin and cytoplasmic PTK6 that facilitates tumor progression in HCC patients. Here, PSPC1 is linked to neoplasm.